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eration and neuronal differentiation upon treatment with RA.
The activity RA was not affected by the encapsulation and pu-
riﬁcation processes. Growth inhibitory effects and morphologic
differentiation into neuronal cell was observed indicating the
suitability of the developed formulation for neuronal regeneration
purposes.
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Macrophages are characterized as having an M1 or M2 phenotype
based on receptor expression, cytokine and effector molecule
production, and function. Classically activated (M1) macrophages
produce pro-inﬂammatory cytokines and reactive oxygen inter-
mediates and efﬁciently present antigen. Alternatively activated
(M2) macrophages produce minimal pro-inﬂammatory cytokines
and possess the ability to facilitate tissue repair/regeneration.
Effects of macrophage phenotype upon tissue remodeling in the
context of regenerative medicine are largely unknown, but the
phenotypic proﬁle may provide a tool by which constructive tis-
sue remodeling can be predicted/promoted.
The objectives of this study were to determine the effects of
a cellular component (autologous or xenogeneic) within an im-
planted extracellular matrix (ECM) scaffold upon macrophage
phenotype, and to determine the relationship between macrophage
phenotype and tissue remodeling.
Partial-thickness defects in the abdominal wall musculature of
Sprague-Dawley rats were repaired with cellular autologous body
wall tissue, acellular allogeneic rat body wall ECM, cellular xe-
nogeneic pig urinary bladder tissue, or acellular xenogeneic pig
urinary bladder ECM. At 3, 7, 14, and 28 days the host tissue
response was characterized using histologic, immunohistochemi-
cal, and RT-PCR methods.
Acellular test articles elicited a larger M2 response than cellular
test articles and resulted in more constructive remodeling, while
those containing a cellular component, even an autologous cellular
component, elicited a more prominent M1 response and resulted in
deposition of dense connective tissue and/or scarring.
We conclude that the presence of cells does affect macrophage
polarization following implantation of an ECM scaffold, and that
macrophage phenotype is associated with tissue-remodeling out-
come.
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One of the open issues in the Tissue Engineering area is whether
scaffolds are needed at all to regenerate many tissue defects. This
is a fundamental question that may be answered by providing
clear evidence of success by scaffold-less tissue regeneration
strategies. In its absence, many groups within this research com-
munity are focused in the development of scaffold-dependent
strategies.
Natural-based biomaterials have been proposed and explored
to meet the requirements of many applications in the Tissue
Engineering and Regenerative Medicine. Among the important
characteristics of those biomaterials it should be highlighted the
easy biodegradation by normal metabolic pathways, the low cy-
totoxicity and low immunogenic reaction upon implantation and
the myriad of properties obtained by combination of thosematerials
with other biodegradable polymers. This later strategy has been
pursued in our lab in the quest to obtain scaffolds that effectively
help, assist and drive cells to regenerate connective tissues.
Many sources of cells have been considered for tissue engi-
neering. Embryonic and adult stem cells are among the most
promising to achieve the cell numbers required to have therapeutic
relevance. The ethical and political constraints surrounding em-
bryonic stem cell line derivation led most research efforts to
concentrate in adult stem cells. We have been using adult stem
cells from different sources for bone and cartilage tissue engi-
neering applications.
This presentation will review our latest developments in tissue
engineering of bone and cartilage using natural-based biodegrad-
able scaffolds with relevant cells both in-vitro and in-vivo.
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Over the last decade, we have witnessed an increased recognition
of the importance of 3D culture models to study various aspects of
cell physiology and pathology, as well as to engineer implantable
tissues. Given the crucial role that bioreactors play in establishing
a comprehensive level of monitoring and control over speciﬁc
environmental factors in 3D cultures, we review herein the mani-
fold potentialities of bioreactor systems in the translational para-
digm of Tissue Engineering (TE) from bench to bedside. In
particular, we will highlight their functions as:
1) Pragmatic tools for tissue engineers, making up for limitations
of conventional manual and static techniques (e.g., seeding and
culture of cells and engineered constructs), enabling automation
and allowing physical conditioning of the developing tissues;
2) 3D culture model systems, enabling to recapitulate speciﬁc
aspects of the actual in vivo milieu and, when properly integrated
with computational modelling efforts and sensing and control tech-
niques, to address challenging scientiﬁc questions (e.g. elucidation
of cell function and tissue development mechanisms);
3) Tissue manufacturing devices, implementing bioprocesses so
as to support safe, standardized, scaleable, traceable and possibly
cost-effective production of grafts for clinical use (e.g. automating
conventional cell and tissue culture processes, streamlining graft
manufacturing within centralized and de-centralized production
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